RSS

Destiny Pharma

Clinical stage biotechnology company, Destiny Pharma, has announced that the US Food and Drug Administration (FDA) has accepted its investigational new drug application (IND) for its lead clinical drug candidate, XF-73. more

News

Destiny Pharma have announced the results of a US clinical trial of the new preventive anti-bacterial drug exeporfinium chloride. more

News

The O’Neill review into antimicrobial resistance (AMR) challenges governments, industry and the medical profession to get to grips with bacterial resistance to antibiotics, “one of the biggest health threats facing mankind” more

Opinion